Yong Cang

Yong Cang is the Co-founder and CSO of Degron Therapeutics. He is a scientific leader in targeted protein degradation, ubiquitin ligase biology and cancer immunotherapy with 30+ publications in top biomedical journals. Dr. Cang pioneers novel molecular glue degrader discovery strategies, with a focus on screening approach development and mechanistic understanding of interactions between molecular glue drugs, ubiquitin ligases and neo-substrates. Dr. Cang is a professor and head of the Laboratory of Targeted Protein Degradation in the School of Life Science and Technology of ShanghaiTech University. He previously was an assistant professor in the NCI-designated Cancer Center of Sanford Burnham Prebys Medical Discovery Institute and a professor of Zhejiang University. Dr. Cang consulted for pharmaceutical industry and venture funds.

Dr. Cang received a BS from Fudan University and a PhD in Molecular Genetics from the Albert Einstein College of Medicine. He completed his postdoctoral training with Professor Stephen Goff at Columbia University and HHMI.